Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Por:
Roos, I, Sharmin, S, Malpas, C, Ozakbas, S, Lechner-Scott, J, Hodgkinson, S, Alroughani, R, Izquierdo, G, Madueño, SE, Boz, C, van der Walt, A, Butzkueven, H, Buzzard, K, Skibina, O, Foschi, M, Grand'Maison, F, John, N, Grammond, P, Terzi, M, Prévost, J, Barnett, M, Laureys, G, Van Hijfte, L, Sanchez, JL, Blanco, Y, Oh, J, Mccombe, P, Tello, CR, Soysal, A, Prat, A, Girard, M, Duquette, P, Yamout, BI, Khoury, S, Van Pesch, V, Macdonell, R, Sá, MJ, Slee, M, Kuhle, J, Maimone, D, Spitaleri, DLA, Willekens, B, Al-Asmi, A, Robertson, N, Coles, A, Brown, JWL and Kalincik, T
Publicada:
1 oct 2023
Resumen:
|